Factors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but...

Descripción completa

Detalles Bibliográficos
Autores: Ortiz-Maldonado Gibson, Valentín, Rives Solà, Susana, Español Rego, Marta, Alonso Saladrigues, A., Montoro, Mercedes, Magnano, Laura, Giné Soca, Eva, Pascal i Capdevila, Mariona, Díaz Beyà, Marina, Castellà Castellà, Maria, Català, Albert, Faura, Anna, Rodríguez Lobato, Luis Gerardo, Oliver Caldés, Aina, Martínez-Roca, Alexandra, Rovira, Montserrat, González Navarro, E. Azucena, Ortega, Juan Ramón, Cid Vidal, Joan, Lozano, Miquel, García Rey, Enric, Fernández, Sara (Fernández García), Castro Rebollo, Pedro, Jordán García, Iolanda, Villamor i Casas, Neus, Aymerich Gregorio, Marta, Torrebadell Burriel, Montserrat, Deyá, Angela, Fernández de Larrea Rodríguez, Carlos José, Benítez-Ribas, Daniel, Trias, Esteve, Varea, Sara, Calvo Rojas, Gonzalo, Esteve Reyner, Jordi, Urbano Ispizua, Álvaro, Juan, Manel, Delgado, Julio (Delgado González)
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/193208
Acceso en línea:https://hdl.handle.net/2445/193208
Access Level:acceso abierto
Palabra clave:Leucèmia limfocítica crònica
Cèl·lules canceroses
Teràpia cel·lular
Antígens CD
Immunoteràpia
Receptors cel·lulars
Chronic lymphocytic leukemia
Cancer cells
Cellular therapy
CD antigens
Immunotheraphy
Cell receptors
Descripción
Sumario:The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but these are generally transient unless followed by alloHCT. Chimeric antigen receptors (CAR) targeting CD19 have shown promising results in R/R ALL, and one of these products (tisagenlecleucel) has been approved for the treatment of patients with R/R ALL up to 25 years of age.

Similares en LA Referencia